Drug intelligence / Profile preview

IMC-2019

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

IMC-2019 is a stem cell therapy candidate being developed by ImmuneCyte Life Sciences for the treatment of non-union fractures (NUF). The therapy is produced using the company's proprietary AutoSTEM platform, which is designed for the automated and standardized manufacturing of stem cells. IMC-2019 aims to address the clinical challenge of fractures that fail to heal spontaneously by providing regenerative cellular components to the injury site to stimulate osteogenesis and facilitate bone repair. It is currently in the preclinical and pilot study stages of development.

Beyond the preview

Go deeper on IMC-2019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-2019.

Explore the full profile